GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tsumura & Co (TSE:4540) » Definitions » ROCE %

Tsumura (TSE:4540) ROCE % : 11.27% (As of Dec. 2023)


View and export this data going back to 1980. Start your Free Trial

What is Tsumura ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tsumura's annualized ROCE % for the quarter that ended in Dec. 2023 was 11.27%.


Tsumura ROCE % Historical Data

The historical data trend for Tsumura's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsumura ROCE % Chart

Tsumura Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.06 7.48 7.77 8.94 7.11

Tsumura Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.70 1.72 6.89 7.50 11.27

Tsumura ROCE % Calculation

Tsumura's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=23274/( ( (350981 - 45875) + (396813 - 47205) )/ 2 )
=23274/( (305106+349608)/ 2 )
=23274/327357
=7.11 %

Tsumura's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=40996/( ( (416840 - 49910) + (418272 - 57608) )/ 2 )
=40996/( ( 366930 + 360664 )/ 2 )
=40996/363797
=11.27 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tsumura  (TSE:4540) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Tsumura ROCE % Related Terms

Thank you for viewing the detailed overview of Tsumura's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tsumura (TSE:4540) Business Description

Traded in Other Exchanges
Address
2-17-11, Akasaka, Minato-ku, Tokyo, JPN, 107-8521
Tsumura & Co is a specialty and generic drug manufacturing company. The company generates most of its revenue through prescription Kampo products, followed by over-the-counter medicines. Tsumura promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company considers strategic collaboration agreements to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Tsumura (TSE:4540) Headlines

No Headlines